The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells
Open Access
- 20 August 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (8) , 1089
Abstract
Proteasomes play an important role in the physiology of cancer cells, and inhibition of their activity may be used as a promising therapeutic strategy against glioblastoma (GBM). Although certain proteasome inhibitors (PIs) have been approved for the treatment of other malignancies, they have limited effectiveness against GBM due to low brain bioavailability. Marizomib (MZB) is an irreversible, second-generation proteasome inhibitor, which unlike other PIs can penetrate through the blood–brain barrier, making it a promising therapeutic tool in brain malignancies. The antitumor activity of MZB was investigated in LN229 and U118 cells. The MTT test and the ATP-based assay were performed to evaluate cytotoxicity. Flow cytometry analysis was used to determine the apoptotic death of GBM cells. Luminescent assays were used to assess levels of reactive oxygen species (ROS) and the activity of caspase 3/7. RT-qPCR and Western blot analyses were used to determine gene and protein expressions. Marizomib decreased the viability and caused apoptotic death of GBM cells. The proapoptotic effect was accompanied by activation of caspase 3 and overexpression of cl-PARP, Noxa, Cyt C, and DR5. Moreover, treatment with MZB triggered endoplasmic reticulum (ER) stress, as shown by increased expressions of GRP78, IRE1α, p-EIF2α, p-SAPK/JNK, CHOP, ATF6α, and ATF4. On the contrary, overproduction of ROS or increased expressions of ERO1α, LC3 II, Beclin 1, and ATG5 were not detected, suggesting that neither oxidative stress nor autophagy were involved in the process of MZB-induced cell death. Thus, marizomib represents a potentially promising compound for facilitating further progress in brain cancer therapy.Keywords
Funding Information
- Medical University of Bialystok (B.SUB.23.371)
This publication has 50 references indexed in Scilit:
- Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Targeting autophagy, oxidative stress, and ER stress for neurodegenerative disease treatmentJournal of Controlled Release, 2022
- Engineering of marizomib loaded polymeric nanoparticles: In vivo safety profile and In vitro proliferation in hepatocellular carcinomaJournal of Drug Delivery Science and Technology, 2021
- New proteasome inhibitors in the treatment of multiple myelomaHematology, Transfusion and Cell Therapy, 2019
- Enhanced Glioblastoma Targeting Ability of Carfilzomib Enabled by a DA7R-Modified Lipid NanodiskMolecular Pharmaceutics, 2018
- Placental endoplasmic reticulum stress negatively regulates transcription of placental growth factor via ATF4 and ATF6β: implications for the pathophysiology of human pregnancy complicationsThe Journal of Pathology, 2015
- Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell lineTumor Biology, 2015
- Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogsChemico-Biological Interactions, 2011
- Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stressActa Pharmacologica Sinica, 2011
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005